Head and Neck Cancer Trial, Recruiting NCT06309225 Sponsor: Omar Mahmoud Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT06309225
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been confirmed by a pathology test to have squamous cell carcinoma (a type of cancer) located in the oropharynx — this includes the tonsils, base of the tongue, soft palate, or the walls of the oropharynx (the middle part of the throat)
  • People who have measurable disease that can be detected by a physical examination or imaging scan, either at the main tumour site or in nearby lymph nodes
  • People whose cancer tissue has tested positive for a protein called P16, based on a laboratory staining test done at the treating site
  • People whose cancer is at a specific stage — not too advanced and not yet spread to distant parts of the body (clinical stage T1–3, N1–2, M0 according to a standard cancer staging system)
  • People aged 65 or older
  • People whose blood test results, taken within 14 days before registration, show that their blood counts and organ function are within acceptable ranges (including healthy levels of white blood cells, platelets, haemoglobin, liver function markers, and kidney function)

Who may not be able to join:

  • People whose cancer has spread to distant parts of the body (metastatic disease)
  • People whose cancer has come back after previously being treated
  • People whose cancer originated outside the oropharynx region (confirm with trial site)
  • People who have two separate primary cancers occurring at the same time
  • People who have previously had radiation therapy for lymphoma or another cancer
  • People who have previously received systemic treatments, including immunotherapy
  • People with serious ongoing health conditions where life expectancy is estimated to be less than one year
  • People with an autoimmune disease (a condition where the immune system attacks the body's own tissues)
  • People with HIV that is not well controlled

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 904-202-7300

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Omar Mahmoud
Registry
ClinicalTrials.gov
Start date
15 May 2025
Est. completion
30 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Two-year progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov